Yaozu Xiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yaozu Xiang has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
Dandan Wang
State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, Department of Biomedicine, School of Life Sciences and Technology, Tongji University, Shanghai, China
13 shared publicationsKai Jiang
State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, Department of Biomedicine, School of Life Sciences and Technology, Tongji University, Shanghai, China
13 shared publicationsRuhua Deng
State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, Department of Biomedicine, School of Life Sciences and Technology, Tongji University, Shanghai, China
8 shared publicationsXingbo Yang
State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, Department of Biomedicine, School of Life Sciences and Technology, Tongji University, Shanghai, China
8 shared publicationsFeng Chen
Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, School of Life Sciences and Technology, Shanghai Fourth People's Hospital, Tongji University, Shanghai 200434, China
7 shared publicationsYue Xu
Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China
7 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Mitochondria-derived vesicles with bioenergetic units from brown adipose tissue attenuate cardiac remodeling post-myocardial infarction
Post-myocardial infarction remodeling is a major cause of heart failure, with contributions from multiple organs. Brown adipose tissue protects against cardiovascular disease, but the mediators of brown adipose tissue-heart crosstalk and their roles in cardiac remodeling remain elusive. Here, we show that mitochondria-derived vesicles from brown adipose tissue transfer to cardiac macrophages and attenuate pathological remodeling via anti-inflammatory effects. Vesicles containing mitochondrial membranes, rather than mitochondrial matrix, mobilize from brown adipose tissue to the heart in response to stress. VPS35 translocation to mitochondria drives protein packaging into mitochondria-derived vesicles for secretion through extracellular vesicle trafficking machinery. Becn1 deficiency impairs VPS35 translocation, alters mitochondria-derived vesicle cargo, and abolishes brown adipose tissue-mediated cardioprotection. Proteomics identifies mitochondrial respiratory chain complex V as a hallmark of protective mitochondria-derived vesicles. These vesicles enhance reparative cytokine production and oxidative phosphorylation rewiring in macrophages. Purified mitochondria-derived vesicles markedly improve remodeling in male mice. Our study uncovers an interorgan transfer of bioenergetic units that contributes to tissue repair.
- 21 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMitochondria-derived vesicles with bioenergetic units from brown adipose tissue attenuate cardiac remodeling post-myocardial infarction
Post-myocardial infarction remodeling is a major cause of heart failure, with contributions from multiple organs. Brown adipose tissue protects against cardiovascular disease, but the mediators of brown adipose tissue-heart crosstalk and their roles in cardiac remodeling remain elusive. Here, we show that mitochondria-derived vesicles from brown adipose tissue transfer to cardiac macrophages and attenuate pathological remodeling via anti-inflammatory effects. Vesicles containing mitochondrial membranes, rather than mitochondrial matrix, mobilize from brown adipose tissue to the heart in response to stress. VPS35 translocation to mitochondria drives protein packaging into mitochondria-derived vesicles for secretion through extracellular vesicle trafficking machinery. Becn1 deficiency impairs VPS35 translocation, alters mitochondria-derived vesicle cargo, and abolishes brown adipose tissue-mediated cardioprotection. Proteomics identifies mitochondrial respiratory chain complex V as a hallmark of protective mitochondria-derived vesicles. These vesicles enhance reparative cytokine production and oxidative phosphorylation rewiring in macrophages. Purified mitochondria-derived vesicles markedly improve remodeling in male mice. Our study uncovers an interorgan transfer of bioenergetic units that contributes to tissue repair.
- Open Access
- 14 October 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-18
Maternal monocyte-derived IFN-α1 triggers early fetal demise
Early fetal demise (EFD), defined as the absence of cardiac activity in a visible fetus, represents a severe form of pregnancy loss with incompletely understood mechanisms. While genetic factors constitute the primary etiology, emerging evidence implicates maternal immune dysregulation in EFD pathogenesis, though the specific cellular and molecular pathways remain undefined. We performed single-cell RNA sequencing (scRNA-seq) on peripheral blood mononuclear cells (PBMCs) from a 20-subject cohort comprising EFD patients, healthy pregnant women, and non-pregnant controls. Parallel murine studies involved GFP-labeled monocyte transfer into E8.5 pregnant mice, with subsequent embryonic viability assessment. Human villous tissues from EFD and control pregnancies were analyzed alongside functional characterization using primary neonatal rat cardiomyocytes exposed to IFN-α1. ScRNA-seq revealed significant CD14+ monocyte accumulation in EFD patients versus controls. In murine models, adoptively transferred maternal monocytes breached the placental barrier, inducing 25.7% embryonic lethality. EFD villous tissues exhibited CD14+ monocyte infiltration with selective IFN-α1 elevation (absent in IFN-α2). Cardiomyocyte functional assays demonstrated IFN-α1-mediated contractile impairment through significant reduction in beating frequency. These findings establish maternal CD14+ monocytes as key mediators of EFD via IFN-α1-dependent cardiac dysfunction, revealing a targetable immune axis for pregnancy preservation. The study provides the first direct evidence linking monocyte trafficking with embryonic viability, offering new therapeutic paradigms for miscarriage prevention.
- 14 October 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-18
Open AccessMaternal monocyte-derived IFN-α1 triggers early fetal demise
Early fetal demise (EFD), defined as the absence of cardiac activity in a visible fetus, represents a severe form of pregnancy loss with incompletely understood mechanisms. While genetic factors constitute the primary etiology, emerging evidence implicates maternal immune dysregulation in EFD pathogenesis, though the specific cellular and molecular pathways remain undefined. We performed single-cell RNA sequencing (scRNA-seq) on peripheral blood mononuclear cells (PBMCs) from a 20-subject cohort comprising EFD patients, healthy pregnant women, and non-pregnant controls. Parallel murine studies involved GFP-labeled monocyte transfer into E8.5 pregnant mice, with subsequent embryonic viability assessment. Human villous tissues from EFD and control pregnancies were analyzed alongside functional characterization using primary neonatal rat cardiomyocytes exposed to IFN-α1. ScRNA-seq revealed significant CD14+ monocyte accumulation in EFD patients versus controls. In murine models, adoptively transferred maternal monocytes breached the placental barrier, inducing 25.7% embryonic lethality. EFD villous tissues exhibited CD14+ monocyte infiltration with selective IFN-α1 elevation (absent in IFN-α2). Cardiomyocyte functional assays demonstrated IFN-α1-mediated contractile impairment through significant reduction in beating frequency. These findings establish maternal CD14+ monocytes as key mediators of EFD via IFN-α1-dependent cardiac dysfunction, revealing a targetable immune axis for pregnancy preservation. The study provides the first direct evidence linking monocyte trafficking with embryonic viability, offering new therapeutic paradigms for miscarriage prevention.
- Open Access
- 26 April 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-24
Cardiomyocyte-specific NHE1 overexpression confers protection against myocardial infarction during hyperglycemia
Acute hyperglycemia on admission is frequently observed during the early phase after acute myocardial infarction (MI), even without the history of diabetes mellitus. We previously reported that inhibiting Na+/H+ exchanger 1 (NHE1) activity post-MI may improve outcomes, but not in the setting of MI with acute hyperglycemia. However, the precise role of NHE1 in the pathophysiology of MI with acute hyperglycemia remains to be elucidated, and there are no effective strategies for its prevention or treatment. We analyzed 85 post-MI patients, identifying acute hyperglycemia (glucose > 7 mM) in non-diabetic individuals, linked to elevated BNP, CK-MB, and reduced plasma Na+. Using retrospective cohort studies and MI with acute hyperglycemia mouse models, we demonstrated that hyperglycemia exacerbates myocardial injury by reducing extracellular Na+, increasing intracellular Na+, and elevating pH, suggesting NHE1 activation as inferred from the observed intracellular pH (pHi) shift. Cardiomyocyte-specific NHE1 ablation or pharmacological inhibition worsened cardiac dysfunction and fibrosis in MI with acute hyperglycemia, while NHE1 overexpression conferred protection. RNA sequencing and drug screening identified accelerated NHE1 activation via 3% NaCl and lithospermic acid (LA) as a novel strategy to mitigate cardiomyocyte necroptosis, alleviating ischemic injury in MI and ischemia reperfusion models. Hypoxia-hyperglycemia and necroptosis induction models in NHE1-knockout, NHE1-overexpressing, and MLKL-overexpressing cardiomyocytes revealed that NHE1 activation, unlike its protective role in oxygen–glucose deprivation, promotes MLKL degradation via autophagosome-lysosomal pathways, reducing cardiomyocyte death. MLKL knockout and MLKL-NHE1 double knockout mice confirmed that MLKL ablation counteracts NHE1 inhibition’s detrimental effects. Activation of myocardial NHE1 promotes MLKL autophagic degradation, mitigating cardiomyocyte necroptosis and acute hyperglycemia-exacerbated MI, highlighting NHE1 as a hyperglycemia-dependent cardioprotective target. Moderate NHE1 activation may represent a novel therapeutic strategy for MI with acute hyperglycemia. NHE1 activation emerges as a novel therapeutic strategy to reduce infarct size and preserve cardiac function in hyperglycemia-associated myocardial infarction (MI). Accelerated NHE1 activation via lithospermic acid (LA) and 3% NaCl infusion offers a groundbreaking approach for managing MI with acute hyperglycemia. For the first time, we demonstrate that cardiomyocyte NHE1 exacerbates cardiac injury by mediating MLKL degradation during MI with acute hyperglycemia. These findings not only unveil promising candidates for clinical cardiovascular therapy but also provide new insights into the treatment of diverse MI subtypes.
- 26 April 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-24
Open AccessCardiomyocyte-specific NHE1 overexpression confers protection against myocardial infarction during hyperglycemia
Acute hyperglycemia on admission is frequently observed during the early phase after acute myocardial infarction (MI), even without the history of diabetes mellitus. We previously reported that inhibiting Na+/H+ exchanger 1 (NHE1) activity post-MI may improve outcomes, but not in the setting of MI with acute hyperglycemia. However, the precise role of NHE1 in the pathophysiology of MI with acute hyperglycemia remains to be elucidated, and there are no effective strategies for its prevention or treatment. We analyzed 85 post-MI patients, identifying acute hyperglycemia (glucose > 7 mM) in non-diabetic individuals, linked to elevated BNP, CK-MB, and reduced plasma Na+. Using retrospective cohort studies and MI with acute hyperglycemia mouse models, we demonstrated that hyperglycemia exacerbates myocardial injury by reducing extracellular Na+, increasing intracellular Na+, and elevating pH, suggesting NHE1 activation as inferred from the observed intracellular pH (pHi) shift. Cardiomyocyte-specific NHE1 ablation or pharmacological inhibition worsened cardiac dysfunction and fibrosis in MI with acute hyperglycemia, while NHE1 overexpression conferred protection. RNA sequencing and drug screening identified accelerated NHE1 activation via 3% NaCl and lithospermic acid (LA) as a novel strategy to mitigate cardiomyocyte necroptosis, alleviating ischemic injury in MI and ischemia reperfusion models. Hypoxia-hyperglycemia and necroptosis induction models in NHE1-knockout, NHE1-overexpressing, and MLKL-overexpressing cardiomyocytes revealed that NHE1 activation, unlike its protective role in oxygen–glucose deprivation, promotes MLKL degradation via autophagosome-lysosomal pathways, reducing cardiomyocyte death. MLKL knockout and MLKL-NHE1 double knockout mice confirmed that MLKL ablation counteracts NHE1 inhibition’s detrimental effects. Activation of myocardial NHE1 promotes MLKL autophagic degradation, mitigating cardiomyocyte necroptosis and acute hyperglycemia-exacerbated MI, highlighting NHE1 as a hyperglycemia-dependent cardioprotective target. Moderate NHE1 activation may represent a novel therapeutic strategy for MI with acute hyperglycemia. NHE1 activation emerges as a novel therapeutic strategy to reduce infarct size and preserve cardiac function in hyperglycemia-associated myocardial infarction (MI). Accelerated NHE1 activation via lithospermic acid (LA) and 3% NaCl infusion offers a groundbreaking approach for managing MI with acute hyperglycemia. For the first time, we demonstrate that cardiomyocyte NHE1 exacerbates cardiac injury by mediating MLKL degradation during MI with acute hyperglycemia. These findings not only unveil promising candidates for clinical cardiovascular therapy but also provide new insights into the treatment of diverse MI subtypes.
- Top Cited Papers
- 19 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (23) , 2223-2238
Periodontitis-related myocardial fibrosis by expansion of collagen-producing SiglecF+ neutrophils
Backgrounds and Aims: Patients with periodontitis (PD) are prone to developing myocardial infarction (MI), yet the prognosis and mechanisms remain unclear. Given the presumed close association of neutrophils with both conditions, this study aims to elucidate the roles of neutrophils in mediating the interaction between PD and MI. Methods: Three prospective cohorts and PD + MI mouse model were investigated to assess the effects of PD on MI prognosis. Single-cell-RNA sequencing and genome-wide association study were employed to identify the neutrophil subtype involved. To characterize the function of SiglecF+ neutrophils, bone marrow transplantation, Edu-pulse chasing, lineage tracing, and collagen contraction assay were utilized. Adoptive neutrophil transfer, conditional Siglecf knockout and lipid nanoparticles facilitating local SiglecF+ neutrophils depletion was harnessed to explore the roles of SiglecF+ neutrophils in MI repair. Results: Persisting but not short-term PD upset MI prognosis (cardiac fibrosis and function) in human and mice. Bone marrow neutrophils of PD were intrinsically skewed toward longer-lived SiglecF+ neutrophil differentiation, a subtype that was converted by GMCSF or TGFβ in PPARγ-dependent manner. SiglecF+ neutrophils were expanded in infarcted PD heart where they deposit collagen and activate fibroblasts to instigate excessive fibrosis. SiglecF+ neutrophil depletion was efficacious for mitigating fibrosis. Conclusions: This study demonstrated that long-lasting PD-aggravated MI prognosis by expanding scar-associated SiglecF+ neutrophils into the heart and highlighted the clinical relevance of oral health examination for treating MI in a holistic fashion.
- 19 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (23) , 2223-2238
Top Cited PapersPeriodontitis-related myocardial fibrosis by expansion of collagen-producing SiglecF+ neutrophils
Backgrounds and Aims: Patients with periodontitis (PD) are prone to developing myocardial infarction (MI), yet the prognosis and mechanisms remain unclear. Given the presumed close association of neutrophils with both conditions, this study aims to elucidate the roles of neutrophils in mediating the interaction between PD and MI. Methods: Three prospective cohorts and PD + MI mouse model were investigated to assess the effects of PD on MI prognosis. Single-cell-RNA sequencing and genome-wide association study were employed to identify the neutrophil subtype involved. To characterize the function of SiglecF+ neutrophils, bone marrow transplantation, Edu-pulse chasing, lineage tracing, and collagen contraction assay were utilized. Adoptive neutrophil transfer, conditional Siglecf knockout and lipid nanoparticles facilitating local SiglecF+ neutrophils depletion was harnessed to explore the roles of SiglecF+ neutrophils in MI repair. Results: Persisting but not short-term PD upset MI prognosis (cardiac fibrosis and function) in human and mice. Bone marrow neutrophils of PD were intrinsically skewed toward longer-lived SiglecF+ neutrophil differentiation, a subtype that was converted by GMCSF or TGFβ in PPARγ-dependent manner. SiglecF+ neutrophils were expanded in infarcted PD heart where they deposit collagen and activate fibroblasts to instigate excessive fibrosis. SiglecF+ neutrophil depletion was efficacious for mitigating fibrosis. Conclusions: This study demonstrated that long-lasting PD-aggravated MI prognosis by expanding scar-associated SiglecF+ neutrophils into the heart and highlighted the clinical relevance of oral health examination for treating MI in a holistic fashion.
- Open Access
- 4 September 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22 (1) , 1-23
Hyperactivation of ATF4/TGF-β1 signaling contributes to the progressive cardiac fibrosis in Arrhythmogenic cardiomyopathy caused by DSG2 Variant
Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiomyopathy characterized with progressive cardiac fibrosis and heart failure. However, the exact mechanism driving the progression of cardiac fibrosis and heart failure in ACM remains elusive. This study aims to investigate the underlying mechanisms of progressive cardiac fibrosis in ACM caused by newly identified Desmoglein-2 (DSG2) variation. We identified homozygous DSG2F531C variant in a family with 8 ACM patients using whole-exome sequencing and generated Dsg2F536C knock-in mice. Neonatal and adult mouse ventricular myocytes isolated from Dsg2F536C knock-in mice were used. We performed functional, transcriptomic and mass spectrometry analyses to evaluate the mechanisms of ACM caused by DSG2F531C variant. All eight patients with ACM were homozygous for DSG2F531C variant. Dsg2F536C/F536C mice displayed cardiac enlargement, dysfunction, and progressive cardiac fibrosis in both ventricles. Mechanistic investigations revealed that the variant DSG2-F536C protein underwent misfolding, leading to its recognition by BiP within the endoplasmic reticulum, which triggered endoplasmic reticulum stress, activated the PERK-ATF4 signaling pathway and increased ATF4 levels in cardiomyocytes. Increased ATF4 facilitated the expression of TGF-β1 in cardiomyocytes, thereby activating cardiac fibroblasts through paracrine signaling and ultimately promoting cardiac fibrosis in Dsg2F536C/F536C mice. Notably, inhibition of the PERK-ATF4 signaling attenuated progressive cardiac fibrosis and cardiac systolic dysfunction in Dsg2F536C/F536C mice. Hyperactivation of the ATF4/TGF-β1 signaling in cardiomyocytes emerges as a novel mechanism underlying progressive cardiac fibrosis in ACM. Targeting the ATF4/TGF-β1 signaling may be a novel therapeutic target for managing ACM.
- 4 September 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22 (1) , 1-23
Open AccessHyperactivation of ATF4/TGF-β1 signaling contributes to the progressive cardiac fibrosis in Arrhythmogenic cardiomyopathy caused by DSG2 Variant
Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiomyopathy characterized with progressive cardiac fibrosis and heart failure. However, the exact mechanism driving the progression of cardiac fibrosis and heart failure in ACM remains elusive. This study aims to investigate the underlying mechanisms of progressive cardiac fibrosis in ACM caused by newly identified Desmoglein-2 (DSG2) variation. We identified homozygous DSG2F531C variant in a family with 8 ACM patients using whole-exome sequencing and generated Dsg2F536C knock-in mice. Neonatal and adult mouse ventricular myocytes isolated from Dsg2F536C knock-in mice were used. We performed functional, transcriptomic and mass spectrometry analyses to evaluate the mechanisms of ACM caused by DSG2F531C variant. All eight patients with ACM were homozygous for DSG2F531C variant. Dsg2F536C/F536C mice displayed cardiac enlargement, dysfunction, and progressive cardiac fibrosis in both ventricles. Mechanistic investigations revealed that the variant DSG2-F536C protein underwent misfolding, leading to its recognition by BiP within the endoplasmic reticulum, which triggered endoplasmic reticulum stress, activated the PERK-ATF4 signaling pathway and increased ATF4 levels in cardiomyocytes. Increased ATF4 facilitated the expression of TGF-β1 in cardiomyocytes, thereby activating cardiac fibroblasts through paracrine signaling and ultimately promoting cardiac fibrosis in Dsg2F536C/F536C mice. Notably, inhibition of the PERK-ATF4 signaling attenuated progressive cardiac fibrosis and cardiac systolic dysfunction in Dsg2F536C/F536C mice. Hyperactivation of the ATF4/TGF-β1 signaling in cardiomyocytes emerges as a novel mechanism underlying progressive cardiac fibrosis in ACM. Targeting the ATF4/TGF-β1 signaling may be a novel therapeutic target for managing ACM.
- Open Access
- 12 June 2024
- Published by Elsevier in Pharmacological Research
- Vol. 205, 107256
Novel strategies for targeting neutrophil against myocardial infarction
- 12 June 2024
- Published by Elsevier in Pharmacological Research
- Vol. 205, 107256
Open AccessNovel strategies for targeting neutrophil against myocardial infarction
- 4 January 2024
- Published by Elsevier in Biomaterials
- Vol. 305, 122466
Brazilin-Ce nanoparticles attenuate inflammation by de/anti-phosphorylation of IKKβ
- 4 January 2024
- Published by Elsevier in Biomaterials
- Vol. 305, 122466
Brazilin-Ce nanoparticles attenuate inflammation by de/anti-phosphorylation of IKKβ
- Open Access
- 25 September 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (10) , 113174
A transient wave of Bhlhe41+ resident macrophages enables remodeling of the developing infarcted myocardium
- 25 September 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (10) , 113174
Open AccessA transient wave of Bhlhe41+ resident macrophages enables remodeling of the developing infarcted myocardium
- Open Access
- 9 September 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 167, 115448
Molecular insight into arrhythmogenic cardiomyopathy caused by DSG2 mutations
- 9 September 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 167, 115448
Open AccessMolecular insight into arrhythmogenic cardiomyopathy caused by DSG2 mutations
- Open Access
- 3 May 2023
- Published by Elsevier in Molecular Therapy
- Vol. 31 (5) , 1201-1203
Harnessing mitochondrial transplantation to sustain cardiac function: Another step forward
- 3 May 2023
- Published by Elsevier in Molecular Therapy
- Vol. 31 (5) , 1201-1203
Open AccessHarnessing mitochondrial transplantation to sustain cardiac function: Another step forward